Lead Investigator: Craig Nelson, University of California San Francisco
Title of Proposal Research: Change in cognition during antidepressant treatment of late life depression
Vivli Data Request: 7845
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Cognitive impairment is common in late life depression. A large US study of the prevalence of major depression found the rate to be 9.1% in indiviudals over 60 years of age. The US Census Bureau projects there will be 59,710,000 people in the US over the age of 65 in 2022. That translates into 5,433,000 individuals with lifetime major depression. Late life major depression contributes to disability and is an estblished risk factor for further cognitive decline and dementia. Both psychotherapy and antidepressants have been used to treat depression but their relative effectiveness for improving cognition has not been well studied. The field has assumed that if depression is treated successfully, cognition will return to normal, but this is not true. We have performed a systematic search of the literature. 640 citations were intially identified. From this group we found 7 studies with 11 contrasts of 7 antidepressants. Duloxetine was the most commonly studied. Some antidepressants had little effect on cognition (e.g. nortriptyline, paroxetine, citalopram). Duloxetine, vortioxetine, and sertraline had the greatest effects. However, almost all of these studies had incomplete data presented. Understanding which antidepressants have beneficial effects on cognition is crucial to the treatment of depressed patients who are cognitively impaired and may be important in reducing the risk of further cognitive decline.
Requested Studies:
Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression
Data Contributor: Lilly
Study ID: NCT00406848
Sponsor ID: 10815
Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder
Data Contributor: Lilly
Study ID: NCT00062673
Sponsor ID: 6091
Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients
Data Contributor: Lundbeck
Study ID: NCT00811252
Sponsor ID: 12541A